{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T08:19:58Z","timestamp":1770538798393,"version":"3.49.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.eplepsyres.2019.106220","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T19:58:12Z","timestamp":1571255892000},"page":"106220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Tolerability and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy and concomitant psychiatric conditions: Post hoc analysis of a prospective, randomized, double-blind trial"],"prefix":"10.1016","volume":"159","author":[{"given":"Bettina","family":"Schmitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Dimova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daya","family":"Chellun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"De Backer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Gasalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2019.106220_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nrleng.2018.10.006","article-title":"LAM study: effects of lacosamide on behaviour and quality of life in patients with epilepsy","volume":"34","author":"Alfaro","year":"2019","journal-title":"Neurolog\u00eda (English Edition)"},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0010","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1474-4422(12)70105-9","article-title":"Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial","volume":"11","author":"Baulac","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1474-4422(16)30292-7","article-title":"Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial","volume":"16","author":"Baulac","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0020","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/14740338.3.1.1","article-title":"Behavioural effects of the newer antiepileptic drugs: an update","volume":"3","author":"Besag","year":"2004","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.yebeh.2015.09.006","article-title":"Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials","volume":"52","author":"Biton","year":"2015","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/nyas.12513","article-title":"Advances in epilepsy treatment: lacosamide pharmacokinetic profile","volume":"1329","author":"Cawello","year":"2014","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0040","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yebeh.2017.08.039","article-title":"Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy","volume":"76","author":"Chen","year":"2017","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0045","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.seizure.2018.09.014","article-title":"Cross-sensitivity of psychiatric and behavioral side effects with antiepileptic drug use","volume":"62","author":"Chen","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0050","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","article-title":"Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial","volume":"51","author":"Chung","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0055","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Proposal for revised clinical and electroencephalographic classification of epileptic seizures","volume":"22","author":"Commission on Classification and Terminology of the International League Against Epilepsy","year":"1981","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0060","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.yebeh.2004.01.010","article-title":"The impact of comorbid depression on health resource utilization in a community sample of people with epilepsy","volume":"5","author":"Cramer","year":"2004","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0065","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/pcn.12784","article-title":"Lacosamide in bipolar disorder: a 30-day comparison to a retrospective control group treated with other antiepileptics","volume":"72","author":"Cuomo","year":"2018","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0070","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0075","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","article-title":"Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial","volume":"50","author":"Hal\u00e1sz","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0080","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.eplepsyres.2007.06.003","article-title":"Predictors of pharmacoresistant epilepsy","volume":"75","author":"Hitiris","year":"2007","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0085","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12883-015-0305-5","article-title":"Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study","volume":"15","author":"Jacobson","year":"2015","journal-title":"BMC Neurol."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0090","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrneurol.2015.243","article-title":"Management of psychiatric and neurological comorbidities in epilepsy","volume":"12","author":"Kanner","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0095","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.yebeh.2016.06.040","article-title":"Psychiatric comorbidities in epilepsy: should they be considered in the classification of epileptic disorders?","volume":"64","author":"Kanner","year":"2016","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0100","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00228-010-0861-y","article-title":"Psychiatric comorbidity in patients with epilepsy: a population-based study","volume":"66","author":"Karouni","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.yebeh.2016.04.049","article-title":"The effects of lacosamide on cognition, quality-of-life measures, and quality of life in patients with refractory partial epilepsy","volume":"61","author":"Lancman","year":"2016","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0110","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1468-1331.2006.01215.x","article-title":"Diagnosing refractory epilepsy: response to sequential treatment schedules","volume":"13","author":"Mohanraj","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0115","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/j.1368-5031.2005.00731.x","article-title":"Antidepressants and seizures: emphasis on newer agents and clinical implications","volume":"59","author":"Montgomery","year":"2005","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0120","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eplepsyres.2014.12.007","article-title":"The effects of lacosamide on depression and anxiety in patients with epilepsy","volume":"110","author":"Moseley","year":"2015","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0125","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/WCO.0000000000000431","article-title":"Depression in epilepsy","volume":"30","author":"Mula","year":"2017","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0130","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11940-017-0483-0","article-title":"Epilepsy and psychiatric comorbidities: drug selection","volume":"19","author":"Mula","year":"2017","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0135","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.yebeh.2017.05.001","article-title":"Effects of adjunctive lacosamide on mood and quality of life in patients with epilepsy","volume":"73","author":"Nakhutina","year":"2017","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0140","series-title":"Tegretol Summary of Product Characteristics","author":"Novartis Pharmaceuticals UK Ltd","year":"2018"},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0145","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1528-1167.2010.02927.x","article-title":"Comorbidities of epilepsy: results from the Epilepsy Comorbidities and Health (EPIC) survey","volume":"52","author":"Ottman","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0150","first-page":"e1686","article-title":"Psychiatric comorbidities and outcomes in epilepsy patients: an insight from a nationwide inpatient analysis in the United States","volume":"9","author":"Patel","year":"2017","journal-title":"Cureus"},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0155","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.yebeh.2012.09.018","article-title":"Antiepileptic drug effects on mood and behavior: molecular targets","volume":"26","author":"Perucca","year":"2013","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0160","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1212\/WNL.0b013e3181f25b16","article-title":"Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients","volume":"75","author":"Petrovski","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0165","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2165\/11599780-000000000-00000","article-title":"Beneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy: a summary of prevalence, underlying mechanisms and data limitations","volume":"26","author":"Piedad","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0170","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.yebeh.2017.10.032","article-title":"Effect of lacosamide on depression and anxiety symptoms in patients with focal refractory epilepsy: a prospective multicenter study","volume":"79","author":"Rocamora","year":"2018","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0175","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1136\/jnnp-2011-301999","article-title":"The LaLiMo trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy\u2014an open-label, prospective, randomised controlled multicenter study","volume":"83","author":"Rosenow","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0180","article-title":"Tolerability of lacosamide and controlled-release carbamazepine monotherapy by number of comorbid conditions: post hoc analysis of a prospective randomized double-blind trial in adults with newly diagnosed epilepsy","author":"Ryan","year":"2017","journal-title":"American Epilepsy Society Annual Meeting 2017"},{"issue":"Suppl. 2","key":"10.1016\/j.eplepsyres.2019.106220_bib0185","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1528-1167.2006.00684.x","article-title":"Effects of antiepileptic drugs on mood and behavior","volume":"47","author":"Schmitz","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0190","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/epi.12934","article-title":"Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America","volume":"56","author":"Sperling","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0195","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.yebeh.2016.02.041","article-title":"A long-term noninterventional safety study of adjunctive lacosamide therapy in patients with epilepsy and uncontrolled partial-onset seizures","volume":"58","author":"Steinhoff","year":"2016","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0200","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.yebeh.2017.04.003","article-title":"Psychiatric side effects and antiepileptic drugs: observations from prospective audits","volume":"71","author":"Stephen","year":"2017","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0205","series-title":"Vimpat\u00ae (Lacosamide) C-V Prescribing Information","author":"UCB Inc","year":"2019"},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0210","series-title":"Vimpat\u00ae (Lacosamide) Summary of Product Characteristics","author":"UCB Pharma SA","year":"2018"},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0215","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jns.2014.05.043","article-title":"Epilepsy and its main psychiatric comorbidities in adults and children","volume":"343","author":"Verrotti","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.eplepsyres.2019.106220_bib0220","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/epi.12681","article-title":"Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study","volume":"55","author":"Wechsler","year":"2014","journal-title":"Epilepsia"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092012111930453X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092012111930453X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:41:45Z","timestamp":1760276505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092012111930453X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":44,"alternative-id":["S092012111930453X"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2019.106220","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolerability and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy and concomitant psychiatric conditions: Post hoc analysis of a prospective, randomized, double-blind trial","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2019.106220","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106220"}}